The global microbiome sequencing market is expected to grow from $1.5 billion in 2024 and is projected to reach $3.7 billion by the end of 2029, at a compound annual growth rate (CAGR) of 19.3% during the forecast period of 2024 to 2029.
Next-generation sequencing (NGS) technologies have transformed the discipline by providing high-throughput, affordable analysis of microbial communities with the ability to sequence millions of DNA fragments at once. By combining microbiome data with genomics, proteomics and metabolomics, researchers have gained a full understanding of microbial functions in health and disease. In addition, the creation of smaller, less expensive sequencing instruments, such as Illumina's MiSeq i100 line, has placed sequencing technologies within reach of smaller research and clinical labs. Organizations are making significant investments in R&D to create affordable sequencing platforms, bioinformatics software and data analysis solutions enabled by AI to enhance precision and efficiency. Strategic partnerships and grants also enhance research in microbiomes, leading to the development of new applications in precision medicine and microbiome therapeutics.
This report analyzes the macroeconomic factors affecting the market. Market drivers, restraints and opportunities are identified. The report covers the regulatory landscape, recent technologies and patents in the market, as well as innovations in products and performance. The report also covers the competitive landscape, ESG factors and profiles of leading companies.
Regional analysis covers North America (U.S., Canada and Mexico), Europe (U.K., Germany, France, Italy, Spain and Rest of Europe), Asia-Pacific (Japan, China, India, South Korea, Australia and Rest of Asia-Pacific), Middle East and Africa (MEA) and South America (Brazil, Argentina and Rest of South America).
Next-generation sequencing (NGS) technologies have transformed the discipline by providing high-throughput, affordable analysis of microbial communities with the ability to sequence millions of DNA fragments at once. By combining microbiome data with genomics, proteomics and metabolomics, researchers have gained a full understanding of microbial functions in health and disease. In addition, the creation of smaller, less expensive sequencing instruments, such as Illumina's MiSeq i100 line, has placed sequencing technologies within reach of smaller research and clinical labs. Organizations are making significant investments in R&D to create affordable sequencing platforms, bioinformatics software and data analysis solutions enabled by AI to enhance precision and efficiency. Strategic partnerships and grants also enhance research in microbiomes, leading to the development of new applications in precision medicine and microbiome therapeutics.
Report Scope
The report analyzes the microbiome sequencing market by component, sequencing technology, laboratory type, application and end user, offering insights into key trends and growth drivers. The study concludes with an analysis of leading companies and their offerings. The base year for the study is 2023, the estimated year is 2024 with projections through 2029, including compound annual growth rate (CAGR) for the forecast period.This report analyzes the macroeconomic factors affecting the market. Market drivers, restraints and opportunities are identified. The report covers the regulatory landscape, recent technologies and patents in the market, as well as innovations in products and performance. The report also covers the competitive landscape, ESG factors and profiles of leading companies.
Regional analysis covers North America (U.S., Canada and Mexico), Europe (U.K., Germany, France, Italy, Spain and Rest of Europe), Asia-Pacific (Japan, China, India, South Korea, Australia and Rest of Asia-Pacific), Middle East and Africa (MEA) and South America (Brazil, Argentina and Rest of South America).
The report includes:
- 50 data tables and 51 additional tables
- Analyses of the global market trends for microbiome sequencing technologies, with revenue data from 2021-2024, and projected CAGRs through 2029
- Estimates of the size and revenue prospects for the global market, along with a market share analysis by sequencing technology, component, laboratory type, application, end user and region
- Facts and figures pertaining to the market dynamics, technological advances, regulations, and the impact of macroeconomic factors
- Insights derived from the Porter’s Five Forces model, as well as global supply chain and PESTLE analyses
- A look at the emerging trends and opportunities in microbiome-based therapeutics, clinical trials
- Evaluation of recent patent activity and key granted and published patents
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
- Analysis of the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
- Profiles of leading companies including Illumina Inc., Qiagen, Thermo Fisher Scientific Inc., Oxford Nanopore Technologies Plc., and PacBio.
Table of Contents
Chapter 1 Executive Summary
Chapter 2 Market Overview
Chapter 3 Market Dynamics
Chapter 4 Regulatory Landscape
Chapter 5 Emerging Technologies and Patent Analysis
Chapter 6 Market Segment Analysis
Chapter 7 Competitive Landscape
Chapter 8 Environmental, Social, and Governance (ESG) Perspective
Chapter 9 Appendix
List of Tables
List of Figures
Companies Mentioned
- BaseClear BV
- CD Genomics
- Charles River Laboratories
- CosmosID
- Crown Bioscience
- Danaher Corp.
- Eurofins Scientific
- Illumina Inc.
- Mérieux NutriSciences
- Microbiome Insights
- Novogene Co. Ltd.
- Oxford Nanopore Technologies plc
- PacBio
- QIAGEN
- Thermo Fisher Scientific Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 124 |
| Published | May 2025 |
| Forecast Period | 2024 - 2029 |
| Estimated Market Value ( USD | $ 1.5 Billion |
| Forecasted Market Value ( USD | $ 3.7 Billion |
| Compound Annual Growth Rate | 19.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
